Drug-drug combination map.

Fig 2 depicts the pairwise drug-drug combinations extracted from phase III and IV ovarian cancer clinical trials of the 43 drugs used in these combinations. The edge width corresponds to the number of the studied drug-drug combination with combinations already used in the clinical setting indicated by a red edge. Drugs having at least one protein target assigned have a grey background, whereas drugs not directly targeting specific proteins but merely interfering with DNA are displayed with a white background.